Antifungal dynamics of LY 303366, an investigational echinocandin B analog, against Candida ssp.

No abstract is available for this paper.

• Publication year

  1996

• Venue

  Diagnostic microbiology and infectious disease

• Publication date

  1996-11-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/S0732-8893(96)00202-7PMID 9078447
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Epidemiology of candidiasis.

  1995cited by this paper
• Epidemiology of nosocomial fungal infections, with emphasis on Candida species.

  1995cited by this paper
• Antibiotics that inhibit fungal cell wall development.

  1994cited by this paper

• Environmental innovation: polyaniline–cuttlebone nanocomposite as a potent antimicrobial agent and a synergistic barrier against doxorubicin-induced toxicity

  2025cites this paper
• Antifungal efficacy of Citrusfusion mediated silver nanoparticles in Candida species

  2025cites this paper
• Eco-friendly innovation: Development of a multifunctional polyaniline-cuttlebone nanocomposite as a synergistic shield against doxorubicin-induced toxicity and a powerful antimicrobial agent.

  2025cites this paper
• Investigation of ternary Zn–Co–Fe layered double hydroxide as a multifunctional 2D layered adsorbent for moxifloxacin and antifungal disinfection

  2024cites this paper
• Antifungal activity of eumelanin-inspired indoylenepheyleneethynylene against Cryptococcus neoformans

  2024influential citation
• Remediation of Caffeine from Aqueous Solutions Using Waste-Derived Adsorbents: A Polyaniline/Cuttlefish Bone Nanocomposite for Pollutant Removal

  2024cites this paper
• In Vitro Susceptibility Tests in the Context of Antifungal Resistance: Beyond Minimum Inhibitory Concentration in Candida spp.

  2023cites this paper
• Antifungal Activity of Chitosan Polymeric Nanoparticles and Correlation with Their pH Against Mucor circinelloides Causing Mucormycosis, Along with Penicillium notatum and Aspergillus Species

  2023influential citation
• DectiSomes: C-type lectin receptor-targeted liposomes as pan-antifungal drugs.

  2023cites this paper
• Efficacy and mechanism of actions of natural antimicrobial drugs.

  2020cites this paper
• The emerging role of computational design in peptide macrocycle drug discovery

  2020cites this paper
• Antifungal activity study of the monoterpene thymol against Cryptococcus neoformans

  2018cites this paper
• Avaliação da atividade antifúngica in vitro das folhas de Xylosma ciliatifolia (Clos) Eichler (Salicaceae) frente a linhagens de Cryptococcus gattii e Cryptococcus neoformans

  2018cites this paper
• Estudo da atividade antifúrgica do timol frente ás cepas De cryptococcus neoformans.

  2017cites this paper
• SCY-078 Is Fungicidal against Candida Species in Time-Kill Studies

  2017cites this paper
• Study of the antifungal potential of (r)-(+)-citronellal and its association with therapeutic agents used in the treatment of vulvovaginal candidiasis = Estudo do potencial antifúngico do (r)-(+)-citronelal e sua associação com agentes terapêuticos utilizados no tratamento da candidíase vulvovaginal

  2017cites this paper
• In vitro anti-Candida activity and mechanism of action of the flavonoid isolated from Praxelis clematidea against Candida albicans species -

  2016influential citation
• ACTIVITY ANTI-C. TROPICALIS AND EFFECTS OF THE COMBINATION OF (S)-(-)- CITRONELLAL WITH FOUR ANTIFUNGAL APPLIED IN VULVOVAGINAL CANDIDIASIS Original Article

  2016cites this paper
• Antibacterial and hemolytic activities of Mimosa tenuiflora (Willd) Poir. (Mimosoidea)

  2015cites this paper
• In Vitro Activity of Caspofungin Against Fluconazole-Resistant Candida Species Isolated From Clinical Samples in Iran

  2015cites this paper
• Inhibition of adherence of C. albicans to dental implants and cover screws by Cymbopogon nardus essential oil and citronellal

  2015cites this paper
• PURIFICAÇÃO, CARACTERIZAÇÃO E ATIVIDADES BIOLÓGICAS DE UMA LECTINA DA ESPONJA MARINHA Aplysina fulva (AFL).

  2014cites this paper
• Evaluation of Antifungal Activity and Mechanism of Action of Citral against Candida albicans

  2014cites this paper
• Atividade biológica do óleo essencial de Cymbopogon nardus e do fitoconstituinte citronelal sobre cepas de Candida envolvidas com infecções peri-implantares

  2014cites this paper
• Antibacterial activity of the essential oil of Citrus limon against multidrug resistant Acinetobacter strains

  2013cites this paper
• Chemical composition and antibacterial activity of essential oil of a Croton rhamnifolioides leaves Pax & Hoffm Composição química e atividade antibacteriana do óleo essencial das folhas de Croton rhamnifolioides Pax & Hoffm

  2013cites this paper
• Antifungal activity of Cymbopogon winterianus jowitt ex bor against Candida albicans

  2011cites this paper
• Safety and Efficacy Data for High-Dose Caspofungin

  2010cites this paper
• Microdilution procedure for antifungal susceptibility testing of Paracoccidioides brasiliensis to amphotericin b and itraconazole

  2009cites this paper
• Anidulafungin Is Fungicidal and Exerts a Variety of Postantifungal Effects against Candida albicans, C. glabrata, C. parapsilosis, and C. krusei isolates

  2009cites this paper
• In Vivo Pharmacodynamic Target Investigation for Micafungin against Candida albicans and C. glabrata in a Neutropenic Murine Candidiasis Model

  2008cites this paper
• Nueva aportación en terapia antifúngica: Anidulafungina. Aspectos farmacológicos de la anidulafungina

  2008cites this paper
• [Anidulafungin: a new therapeutic approach in antifungal therapy. Pharmacology of anidulafungin].

  2008cites this paper
• [Anidulafungin].

  2008cites this paper
• In Vivo Pharmacodynamic Characterization of Anidulafungin in a Neutropenic Murine Candidiasis Model

  2007cites this paper
• Anidulafungin: a novel echinocandin.

  2006cites this paper
• Emerging echinocandins for treatment of invasive fungal infections

  2006cites this paper
• Actividad in vitro de las equinocandinas ¿Cómo debe evaluarse?

  2005cites this paper
• [In vitro activity of the echinocandins. How should it be evaluated?].

  2005cites this paper
• Anidulafungin: a new echinocandin with a novel profile.

  2005cites this paper
• Determination of Fungicidal Activities against Yeasts and Molds: Lessons Learned from Bactericidal Testing and the Need for Standardization

  2004cites this paper
• Anidulafungin: an echinocandin antifungal

  2004cites this paper
• Atividade biológica de uma nova formulação de anfotericina B solubilizada em nanofragmentos catiônicos de bicamada de brometo de dioctadecildimetilamônio

  2004cites this paper
• In vitro antifungal activities of anidulafungin and micafungin, licensed agents and the investigational triazole posaconazole as determined by NCCLS methods for 12,052 fungal isolates: review of the literature.

  2003cites this paper
• In Vivo Pharmacodynamics of HMR 3270, a Glucan Synthase Inhibitor, in a Murine Candidiasis Model

  2003cites this paper
• Caspofungin Activity against Clinical Isolates of Fluconazole-Resistant Candida

  2003cites this paper
• In Vitro Activities of Caspofungin Compared with Those of Fluconazole and Itraconazole against 3,959 Clinical Isolates of Candida spp., Including 157 Fluconazole-Resistant Isolates

  2003cites this paper
• The echinocandin antifungals: an overview of the pharmacology, spectrum and clinical efficacy

  2003influential citation
• CAY-I, a fungicidal saponin from Capsicum sp. fruit.

  2002cites this paper
• Evaluation of amphotericin B and flucytosine in combination against Candida albicans and Cryptococcus neoformans using time-kill methodology.

  2001cites this paper
• Current and future approaches to antimycotic treatment in the era of resistant fungi and immunocompromised hosts.

  2001cites this paper
• Antifungal susceptibility testing. New technology and clinical applications.

  2001cites this paper
• Pharmacokinetic and Pharmacodynamic Modeling of Anidulafungin (LY303366): Reappraisal of Its Efficacy in Neutropenic Animal Models of Opportunistic Mycoses Using Optimal Plasma Sampling

  2001cites this paper
• In Vitro Susceptibility Testing Methods for Caspofungin against Aspergillus andFusarium Isolates

  2001cites this paper
• Glucan synthase inhibitors as antifungal agents.

  2001cites this paper
• Antifungal Susceptibility Testing: Practical Aspects and Current Challenges

  2001cites this paper
• Dosage-Dependent Antifungal Efficacy of V-Echinocandin (LY303366) against Experimental Fluconazole-Resistant Oropharyngeal and Esophageal Candidiasis

  2001cites this paper
• Antifungal susceptibility testing. New technology and clinical applications.

  2001cites this paper
• Antifungal Pharmacodynamics: Concentration‐Effect Relationships in Vitro and in Vivo

  2001cites this paper
• Investigational Antifungal Agents

  2001cites this paper
• Efficacies of Two New Antifungal Agents, the Triazole Ravuconazole and the Echinocandin LY-303366, in an Experimental Model of Invasive Aspergillosis

  2000cites this paper
• In Vitro Pharmacodynamic Characteristics of Nystatin Including Time-Kill and Postantifungal Effect

  2000cites this paper
• Postantifungal Effects of Echinocandin, Azole, and Polyene Antifungal Agents against Candida albicans andCryptococcus neoformans

  2000cites this paper
• D-cecropin B: proteolytic resistance, lethality for pathogenic fungi and binding properties.

  2000cites this paper
• Antifungal Pharmacodynamics: Review of the Literature and Clinical Applications

  2000cites this paper
• Antifungal peptides: potential candidates for the treatment of fungal infections

  2000cites this paper
• Antifungal Peptides: Novel Therapeutic Compounds against Emerging Pathogens

  1999cites this paper
• Antifungal Activity of LY303366, a Novel Echinocandin B, in Experimental Disseminated Candidiasis in Rabbits

  1999cites this paper
• [Review article. Molecular basis of antimycotic therapy].

  1999cites this paper
• übersichtsartikel Molekulare Grundlagen der antimykotischen Therapie: Review Article: Molecular basis of antimycotic therapy

  1999cites this paper
• Compounds against Emerging Pathogens Antifungal Peptides : Novel Therapeutic

  1998cites this paper
• Evaluation of Endpoints for Antifungal Susceptibility Determinations with LY303366

  1998influential citation
• Influence of Test Conditions on Antifungal Time-Kill Curve Results: Proposal for Standardized Methods

  1998cites this paper
• Susceptibilities of Candida Species Isolated from the Lower Gastrointestinal Tracts of High-Risk Patients to the New Semisynthetic Echinocandin LY303366 and Other Antifungal Agents

  1998cites this paper
• Antifungal Efficacy, Safety, and Single-Dose Pharmacokinetics of LY303366, a Novel Echinocandin B, in Experimental Pulmonary Aspergillosis in Persistently Neutropenic Rabbits

  1998cites this paper
• In vitro interaction of fluconazole and amphotericin B administered sequentially against Candida albicans: effect of concentration and exposure time.

  1998cites this paper
• In vitro kill curves of a new semisynthetic echinocandin, LY-303366, against fluconazole-sensitive and -resistant Candida species

  1997influential citation
• Update on antifungal resistance.

  1997cites this paper
• Galgiani species and Cryptococcus neoformans . MK-0991 , and fluconazole against Candida echinocandin LY 303366 , the pneumocandin Comparison of the in vitro activities of the

  1997cites this paper
• Comparison of the in vitro activities of the echinocandin LY303366, the pneumocandin MK-0991, and fluconazole against Candida species and Cryptococcus neoformans

  1997cites this paper
• Growth medium effect on the antifungal activity of LY 303366.

  1997cites this paper